SNM: New radioisotope generator improves PET agent production

SALT LAKE CITY—A new radioisotope generator could diversify the number of PET imaging agents, based on research presented at the 57th annual conference of SNM this week.

The researchers reported that the generator, in combination with instant synthesis kits that introduce target constituents like peptides to the mix, could be used to produce molecular imaging agents that enhance the range of targeting capabilities in diagnostic scans, providing physicians with a much broader portrait of how biological processes are working and why.

Using this generator, physicians would be able to inject peptide-labeled agents containing extremely small levels of the targeting peptide, which homes in on biological processes in the body, according to the researchers. Only a small number of PET imaging agents are currently available due to their short half-lives, which require daily production and synthesis at more than 100 radiopharmacies across the country.

Jeffrey Lacy, PhD, president of Houston-based Proportional Technologies and his team reported that the new generator would depend on a longer-lived parent isotope that is relatively easily distributed and obtained, and physicians synthesize and inject the subsequent copper-based agent minutes before scanning.

In this study, investigators miniaturized and redesigned components of a larger-scale generator approved for human investigational studies and tested the system for peptide specific activity using a peptide that targets a melanoma receptor called melanoma-1. Melanoma-bearing mice were injected with the peptide-labeled imaging agent and underwent PET imaging.

According to Lacy and colleagues, tumors showed rapid receptor-specific uptake of the agent with specific activity as high as 200 Ci/umol (a measurement of radioactivity in microcuries per micromolar concentration). Results showed that the generator and kit system were able to instantly label the radioactive copper isotope without further purification.

The agent produced by this system has been shown to be favorable to human studies, and may improve upon the image quality of similar copper-based agents, they reported.

“This generator is one more advanced technology that can improve the treatment of cancer, cardiovascular conditions and other common conditions,” said Lacy.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.